Summary
Clinical studies have suggested that both MDR1 and MRP may play a significant role in the chemosensitivity and outcome of neuroblastoma. To clarify the nature of multidrug resistance (MDR) in this tumour a series of six neuroblastoma cell lines have been characterized with regard to P-glycoprotein, MRP and LRP expression using immunocytochemistry and expression of MDR1, MRP, LRP and topoisomerase II genes using reverse transcription polymerase chain reaction (RT-PCR). By RT-PCR, all lines expressed MRP, five expressed LRP and four expressed MDR1, but protein levels of each of these were variable. Chemosensitization to a range of MDR-associated drugs (vincristine, doxorubicin, etoposide, taxotere, topotecan) and non-MDR-associated drugs (cisplatin, melphalan) by three modulating agents, cyclosporin A, PSC 833 and the novel Biricodar (VX-710; Incel™), was evaluated using a colourimetric cytotoxicity assay (MTS). Alteration of daunorubicin efflux by these agents was evaluated using FACS analysis. Clonogenic assay was used to study the influence of these chemosensitizers on vincristine cytotoxicity. Marked sensitization to vincristine was observed in MDR1-positive lines, and a similar but less consistent effect was seen with taxotere, doxorubicin and etoposide. With MRP-positive, MDR-negative lines, only VX-710 caused consistent sensitization. These data confirm MDR1 and MRP expression as contributory factors in chemoresistance in neuroblastoma and indicate that VX-710 may be a useful modulator of both mechanisms and worthy of clinical evaluation in this tumour.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beck, W. T., Grogan, T. M., Willman, C. L., Cordon Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., Brophy, N. A., Broxterman, H. J., Chan, H. S., Dalton, W. S., Dietel, M., Fojo, A. T., Gascoyne, R. D., Head, D., Houghton, P. J. & Srivastava, D. K. (1996). Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumors: consensus recommendations. Cancer Res 56: 3010–3020.
Beck, W. T., Handgretinger, R., Dopfer, R., Klingebiel, T., Niethanmmer, D. & Gekeler, V. (1995). Expression of MDR1, MRP, topoisomerase Iia/b, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89: 356–363.
Beketic-Oreskovic, L., Duran, G. E., Chen, G., Dumontet, G. & Sikic, B. I. (1995). Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst 87: 1593–1602.
Biedler, J. L. & Spengler, B. A. (1976). Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 191: 185–187.
Biedler, J. L., Helson, L. & Spengler, B. A. (1973). Morphology and growth, tumorigenicity and cytogenetics of human neuroblastoma cells in continuous culture. Cancer Res 33: 2652
Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H. & Bleehen, N. M. (1996). Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 14: 610–618.
Bordow, S. B., Haber, M., Madafiglio, J., Cheung, B., Marshall, G. M. & Norris, M. D. (1994). Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54: 5036–5040.
Bourhis, J., Benard, J., Hartmann, O., Boccon Gibod, L., Lemerle, J. & Riou, G. (1989). Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst 81: 1401–1405.
Cairo, M. S., Siegel, S., Anas, N. & Sender, L. (1989). Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 49: 1063–1066.
Chan, H. S., Haddad, G., Thorner, P. S., DeBoer, G., Lin, Y. P., Ondrusek, N., Yeger, H. & Ling, V. (1991). P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608–1614.
Chan, H. S., DeBoer, G., Haddad, G., Gallie, B. L. & Ling, V. (1995). Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 9: 275–318.
Cowie, F. & Pinkerton, C. R. (1994). Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance [letter]. J Clin Oncol 12: 1998–1999.
Cowie, F. J., Pinkerton, C. R., Phillips, M., Dick, G., Judson, I., McCarthy, P. T. & Flanagan, R. J. (1995). Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. Br J Cancer 71: 877–881.
Deacon, J. M. (1986). The radiobiology of human neuroblastoma. (A thesis submitted to the University of London for the degree of Doctor of Medicine)
Feller, N., Kuiper, C. M., Lankelma, J., Ruhdal, J. K., Scheper, R. J., Pinedo, H. M. & Broxterman, H. J. (1995). Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 72: 543–549.
Futscher, B. W., Blake, L. L., Gerlach, J. G., Grogan, T. M. & Dalton, W. S. (1993). Quantitative polymerase chain reaction analysis of mdr1 mRNA in multiple myeloma cell lines and clinical specimens. Analyt Biochem 213: 421
Germann, U. A., Shlyakher, D., Mason, V. S., Zelle, R. E., Duffy, J. P., Galullo, V., Armistead, D. M., Saunders, J. O., Boger, J. & Harding, M. W. (1997a). Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. Anti-Cancer Drugs 8: 125–140.
Germann, U. A., Ford, P. J., Shlyakher, D., Mason, V. S. & Harding, M. W. (1997b). Chemosensitization and drug accummulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anti-Cancer Drugs 8: 141–155.
Goodwin, C. J., Holt, S. J., Downes, S. & Marshall, N. J. (1995). Microculture tetrazolium assays: a comparison between two new tetrazolium salts, XTT and MTS. J Immunol Methods 179: 95–103.
Helson, C., Zahn, Z. & Helson, L. (1994). Reversion of P-glycoprotein mediated multi-drug resistance to vincristine and adriamycin by PSC 833, a cyclosporine derivative in human neuroblastoma cell lines. Int J Oncol 5: 1037–1042.
Hills, C. A., Kelland, L. R., Abel, G., Siracky, J., Wilson, A. P. & Harrap, K. R. (1989). Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59: 527–534.
Inui, A. (1974). Catecholamine metabolism in a continuous human neuroblastoma cell line (NB-1). Establishment of a continuous cell line (NB-1) and comparative study on catecholamine metabolism in neuroblastoma in vivo and in vitro. Acta Pediatr Jpn 78: 977–989.
Lum, B. L., Fisher, G. A., Brophy, N. A., Yahanda, A. M., Adler, K. M., Kaubisch, S., Halsey, J. & Sikic, B. I. (1993). Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer 72: 3502–3514.
Norris, M. D., Bordow, S. B., Marshall, G. M., Haber, P. S., Cohn, S. L. & Haber, M. (1996). Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. New England Journal of Medicine 334: 231–238.
Peck, R., Marshall, J. L. & Ziessman, H. A. (1995). Preliminary findings from a phase I/II trial of doxorubicin (DOX) and VX-710. [Abstract] AACR, Special Conference in Cancer Research: Novel Strategies Against Resistant Cancers,
Pike, B. L. & Robinson, W. A. (1970). Human bone marrow colony growth in agar-gel. J Cell Pysiol 76: 77–84.
Rowinsky, E. K., Smith, I. & Wang, Y. M. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with Biricodar, a Novel Agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16: 2964–2976.
Stein, U., Walther, W., Laurencot, C. M., Scheffer, G. L., Scheper, R. L. & Shoemaker, R. H. (1997). Tumor necrosis factor-α and expression of the multidrug resistance associated genes LRP and MRP. J Natl Cancer Inst 89: 807–813.
Tumilowicz, J. J., Nichols, W. W., Cholon, J. J. & Greene, A. E. (1970). Definition of a continuous human cell line derived from neuroblastoma. Cancer Res 30: 2110–2118.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Yanagisawa, T., Newman, A., Coley, H. et al. BIRICODAR (VX-710; Incel™): an effective chemosensitizer in neuroblastoma. Br J Cancer 80, 1190–1196 (1999). https://doi.org/10.1038/sj.bjc.6990485
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6990485
This article is cited by
-
Targeting multidrug resistance in cancer by natural chemosensitizers
Bulletin of the National Research Centre (2019)
-
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells
Cancer Chemotherapy and Pharmacology (2013)
-
A protein kinase Cβ inhibitor attenuates multidrug resistance of neuroblastoma cells
BMC Cancer (2003)
-
Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
Cancer Chemotherapy and Pharmacology (2003)